Company Overview and News


Add SNOA
to your dashboard

Headline News

Sonoma Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides

2017-11-11 seekingalpha
The following slide deck was published by Sonoma Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings call. (10-0)

Sonoma Pharmaceuticals' (SNOA) CEO Jim Schutz on Q2 2018 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good afternoon, and welcome to the Sonoma Fiscal Second Quarter 2018 Conference Call. My name is Skylar, and I’ll be your coordinator for today’s call. At this time, all participants are in a listen-only mode. At the end of the call, we will be holding a question-and-answer session with company management. As a reminder, this call is being recorded for replay purposes. (38-0)

Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA)

2017-10-18 accesswire
Sonoma Pharmaceuticals, Inc. ("Sonoma") is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care based upon its proprietary technology, Microcyn®. The Company's products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itching, pain, scarring, and harmful inflammatory responses. (25-0)

Global Scar Treatment Market Size, Share, Development, Growth and Demand Forecast to 2023 - Industry Insight by Type of Treatment by Type of Scars and by End User

2017-10-11 prnewswire
LONDON, Oct. 11, 2017 /PRNewswire/ -- Market Overview Scar treatment in the study refers to the treatment of marks on the skin surface, that appear when the skin is damaged. It includes various products and therapies performed by various dermatologists, cosmetologists and other skin specialists for fading away or completely removing the scars. Based on the type of scar, the global scar treatment market is segmented into topical, surface, laser, injectable and invasive surgical. (177-0)

Sonoma Pharmaceuticals' (SNOA) CEO Jim Schutz on Fiscal Q1 2018 Results - Earnings Call Transcript

2017-08-14 seekingalpha
Good day, ladies and gentlemen, and welcome to Sonoma Pharmaceuticals fiscal first quarter 2018 conference call. Currently, at this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]. Also as a reminder, this conference call is being recorded. (0-4)

PRO Weekly Digest: Hands-On Value Investing With Zander Rosenbluth

2017-07-09 seekingalpha
Examples of hands-on value investing, why micro/small cap is the place to look for deep value and a key theme for short ideas are topics discussed.

After-hours buzz: ACOR, THO & more

2017-06-06 cnbc
Shares of Acorda Pharmaceuticals rose more than 7 percent after the company announced that one of its Parkinson's disease drugs showed significant improvements to patients' motor functions during off periods.

BRIEF-Sonoma Pharmaceuticals says receives two new UAE regulatory approvals, Pediacyn® for atopic dermatitis and Epicyn® for scar management

2017-04-12 reuters
* Sonoma Pharmaceuticals - receives two new united arab emirates regulatory approvals: Pediacyn® for atopic dermatitis and Epicyn® for scar management

Scar Treatment Market Analysis By Product (Topical, Laser, Injectables), By Scar Type (Stretch Marks, Atrophic, Contracture, Hypertrophic & Keloid Scars), By End Use (Hospitals, Clinics, Retail Pharmacies), And Segment Forecasts, 2014 - 2025

2017-03-28 prnewswire
NEW YORK, March 28, 2017 /PRNewswire/ -- The global scar treatment market is expected to reach a value of USD 34.5 billion by 2025, according to a new report by Grand View Research, Inc. Scar treatment industry is developing at a fast rate due to the growing awareness among people regarding esthetics. Appearance of different types of scars poses a huge impact on the day-to-day lifestyle of the victim, thereby affecting their esthetic appeal.

Sonoma Pharmaceuticals's (SNOA) CEO Jim Schutz On Q3 2017 Results - Earnings Call Transcript

2017-02-10 seekingalpha
Good afternoon, and welcome to the Sonoma Fiscal Third Quarter 2017 Conference Call. My name is Brian and I will be your coordinator for today's call. At this time all participants are in a listen-only mode. At the end of the call, we will be holding a question-and-answer session with the company's management. As a reminder, this conference call is being recorded for replay purposes.

CUSIP: 83558L105